Index
-
Market Cap
10.05B
Enterprise Value
9.80B
Income
222.40M
Sales
2.59B
Book/sh
268.30
Cash/sh
60.42
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
7450
IPO
Feb 27, 1980
P/E
45.42
Forward P/E
36.59
PEG
7.23
P/S
3.88
P/B
1.40
P/C
6.20
P/FCF
28.47
EV/EBITDA
22.14
EV/Sales
3.79
Quick Ratio
2.33
Current Ratio
3.14
Debt/Eq
0.19
LT Debt/Eq
0.13
Option/Short
Yes / Yes
EPS (ttm)
8.25
EPS next Y
10.25
EPS next Q
2.23
EPS this Y
-1.73%
EPS next Y
5.10%
EPS next 5Y
5.06%
EPS past 3/5Y
- -26.08%
Sales past 3/5Y
-2.68% 0.29%
EPS Y/Y TTM
-29.25%
Sales Y/Y TTM
1.37%
EPS Q/Q
18.67%
Sales Q/Q
-0.09%
Insider Own
33.25%
Insider Trans
-0.01%
Inst Own
72.03%
Inst Trans
-7.22%
ROA
2.17%
ROE
3.11%
ROIC
2.74%
Gross Margin
51.86%
Oper. Margin
9.08%
Profit Margin
8.59%
SMA20
2.14%
SMA50
0.14%
SMA200
19.42%
Trades
Shs Outstand
21.68M
Shs Float
17.85M
52W High
396.23 -5.38%
52W Low
236.73 58.37%
Volatility
3.22% 3.30%
ATR (14)
11.96
RSI (14)
53.33
Beta
1.06
Rel Volume
0.84
Avg Volume
254.68K
Volume
214,470
Perf Week
-1.60%
Perf Month
-1.29%
Perf Quarter
7.78%
Perf Half Y
45.81%
Perf YTD
23.74%
Perf Year
20.38%
Perf 3Y
30.23%
Perf 5Y
-51.93%
Perf 10Y
127.87%
Prev Close
366.16
Price
374.91
Change %
2.39%
Analysts 10 incl. previous ratings
Rating Distribution 5 Buy · 5 Hold · 0 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside May 15, 2026 Resumed R RBC Capital Mkts
Outperform $320 -14.6% Apr 07, 2026 Downgrade C Citigroup
Buy → Neutral $300 -20.0% Oct 01, 2024 Upgrade C Citigroup
Neutral → Buy $350 → $400 +6.7% Aug 28, 2024 Initiated W Wells Fargo
Equal Weight $340 -9.3% Jun 03, 2024 Resumed J Jefferies
Hold $315 -16.0% Apr 03, 2024 Downgrade C Citigroup
Buy → Neutral $400 → $365 -2.6% Dec 07, 2023 Initiated U UBS
Buy $395 +5.4% Jun 16, 2023 Initiated W Wells Fargo
Overweight $550 +46.7% Dec 07, 2022 Initiated R RBC Capital Mkts
Outperform $565 +50.7% Aug 25, 2022 Initiated C
Outperform $715 +90.7% Jan 28, 2022 Reiterated C Citigroup
Buy $915 → $750 +100.0% Jan 08, 2020 Initiated W Wells Fargo
Overweight $430 +14.7% Jan 07, 2020 Initiated C Citigroup
Buy $450 +20.0% Oct 17, 2018 Initiated G Goldman
Buy $350 -6.6% Sep 20, 2018 Initiated M Morgan Stanley
Equal-Weight $335 -10.6% Feb 16, 2018 Downgrade C
Buy → Neutral Jul 13, 2017 Initiated W Wells Fargo
Outperform Jun 28, 2017 Upgrade D Deutsche Bank
Hold → Buy $220 → $255 -32.0% Jan 18, 2017 Initiated D Deutsche Bank
Hold $195 -48.0% Oct 13, 2016 Initiated C
Buy
Oct-29-26 04:30PM
Oct-27-26 03:32PM
Sep-24-26 06:34AM
Sep-16-26 09:00AM
Sep-08-26 03:37PM
09:00AM
Loading…
Aug-31-26 09:00AM
Aug-05-26 01:02AM
Aug-04-26 10:57PM
04:15PM
Jul-30-26 02:29PM
Jul-23-26 09:00AM
May-22-26 01:25PM
May-18-26 07:57AM
May-17-26 08:03PM
(The Wall Street Journal)
May-08-26 09:00AM
03:19AM
Loading…
May-01-26 03:19AM
Apr-30-26 05:06PM
04:15PM
Apr-16-26 04:15PM
Feb-26-26 07:29PM
Feb-20-26 09:15AM
Feb-19-26 02:42PM
08:33AM
Feb-17-26 10:14AM
Feb-13-26 04:34PM
10:02AM
12:02AM
Feb-12-26 10:10PM
05:59PM
(Associated Press Finance)
05:35PM
04:15PM
Loading…
04:15PM
Jan-29-26 08:30AM
Jan-21-26 08:11AM
08:01AM
Oct-30-25 05:17PM
11:45AM
09:04AM
Oct-29-25 05:55PM
05:23PM
(Associated Press Finance)
04:15PM
Oct-28-25 09:25AM
Oct-24-25 01:30PM
Oct-23-25 11:44AM
10:00AM
Oct-22-25 10:00AM
Oct-16-25 05:30PM
Oct-08-25 06:12AM
Oct-01-25 07:52PM
(Morningstar Research)
+6.26%
Sep-18-25 10:39AM
Sep-02-25 08:23AM
Sep-01-25 10:17AM
Aug-22-25 07:47PM
(Morningstar Research)
+6.59%
Aug-13-25 08:41AM
Aug-12-25 04:49AM
Aug-02-25 07:48AM
Aug-01-25 12:31PM
(Morningstar Research)
+17.63%
09:00AM
03:39AM
Jul-31-25 05:28PM
(Associated Press Finance)
04:15PM
Jul-30-25 09:28AM
05:08AM
Jul-29-25 10:00AM
04:31AM
04:02AM
Jul-28-25 04:15PM
Jul-25-25 10:44PM
Jul-24-25 10:00AM
Jul-17-25 04:15PM
Jul-16-25 04:07AM
Jul-14-25 08:07AM
Jul-11-25 04:02AM
Jul-10-25 05:19AM
Jul-07-25 09:00AM
Jun-16-25 08:30AM
May-29-25 04:30PM
May-13-25 09:16AM
May-12-25 04:30PM
May-03-25 08:45AM
May-02-25 06:48PM
07:58AM
May-01-25 10:35PM
05:40PM
04:15PM
Apr-29-25 12:59PM
Apr-24-25 10:35AM
10:25AM
10:01AM
Apr-23-25 06:00AM
Apr-22-25 08:09AM
Apr-21-25 08:08AM
Apr-15-25 09:50PM
04:15PM
Apr-13-25 12:48PM
09:51AM
Apr-10-25 01:29PM
(Morningstar Research)
-6.77%
Apr-04-25 08:28PM
Apr-03-25 09:00AM
Mar-31-25 10:00AM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
DiVincenzo Jonathan P. President & COO Oct 24 '26 Option Exercise 0.00 1,869 0 3,832 Oct 27 04:57 PM EVRAN SEDAT EVP, Global Supply Chain Oct 20 '26 Option Exercise 0.00 1,044 0 4,647 Oct 22 05:55 PM Allison Schwartz Director Sep 06 '26 Option Exercise 0.00 92 0 1,768 Sep 09 06:47 PM Allison Schwartz Director Sep 05 '26 Option Exercise 0.00 228 0 1,758 Sep 09 06:47 PM BARRY JAMES EVP, President, LSG Sep 06 '26 Option Exercise 0.00 1,056 0 2,495 Sep 09 06:46 PM BARRY JAMES EVP, President, LSG Sep 05 '26 Option Exercise 0.00 1,027 0 1,808 Sep 09 06:46 PM EVRAN SEDAT EVP, Global Supply Chain Sep 06 '26 Option Exercise 0.00 864 0 3,880 Sep 09 06:46 PM EVRAN SEDAT EVP, Global Supply Chain Sep 05 '26 Option Exercise 0.00 1,027 0 3,345 Sep 09 06:46 PM ENGELHARDT EVA ANETTE EVP, President, CDG Sep 06 '26 Option Exercise 0.00 1,152 0 2,313 Sep 09 06:45 PM ENGELHARDT EVA ANETTE EVP, President, CDG Sep 05 '26 Option Exercise 0.00 1,027 0 1,530 Sep 09 06:45 PM DiVincenzo Jonathan P. President & COO Sep 05 '26 Option Exercise 0.00 1,712 0 2,631 Sep 09 06:45 PM ENLOE COURTNEY C EVP, General Counsel & Sec Sep 06 '26 Option Exercise 0.00 768 0 1,957 Sep 09 06:45 PM ENLOE COURTNEY C EVP, General Counsel & Sec Sep 05 '26 Option Exercise 0.00 685 0 1,435 Sep 09 06:45 PM Mehta Rajat EVP, GBL Commercial Operations Sep 05 '26 Option Exercise 0.00 1,826 0 1,736 Sep 09 06:44 PM Lakkaraju Roop Kalyan EVP, Chief Financial Officer Sep 06 '26 Option Exercise 0.00 1,536 0 4,933 Sep 09 06:42 PM Lakkaraju Roop Kalyan EVP, Chief Financial Officer Sep 05 '26 Option Exercise 0.00 1,370 0 3,956 Sep 09 06:42 PM SCHWARTZ NORMAN D Chairman & CEO Sep 06 '26 Option Exercise 0.00 3,455 0 450,873 Sep 09 06:42 PM SCHWARTZ NORMAN D Chairman & CEO Sep 05 '26 Option Exercise 0.00 4,109 0 450,294 Sep 09 06:42 PM BARRY JAMES EVP, President, LSG Sep 01 '26 Option Exercise 0.00 425 0 935 Sep 03 05:41 PM Allison Schwartz Director Sep 01 '26 Option Exercise 0.00 117 0 1,573 Sep 03 05:38 PM SCHWARTZ NORMAN D Chairman & CEO Sep 01 '26 Option Exercise 0.00 5,087 0 448,521 Sep 03 05:35 PM ENGELHARDT EVA ANETTE EVP, President, CDG Jul 25 '26 Option Exercise 0.00 246 0 592 Jul 28 03:05 PM Alles Institute for Medical Re Director May 28 '26 Proposed Sale 313.28 700 219,296 May 28 03:04 PM ENGELHARDT EVA ANETTE EVP, President, CDG May 11 '26 Sale 246.54 550 135,597 346 May 13 03:38 PM EVA ENGELHARDT Officer May 11 '26 Proposed Sale 246.54 550 135,597 May 11 05:03 PM Lakkaraju Roop Kalyan EVP, Chief Financial Officer Apr 24 '26 Option Exercise 0.00 1,078 0 2,984 Apr 28 12:21 PM ENLOE COURTNEY C EVP, General Counsel & Sec Apr 24 '26 Option Exercise 0.00 186 0 827 Apr 28 12:20 PM Hinckley Greg K Director Apr 21 '26 Option Exercise 0.00 407 0 1,215 Apr 23 03:26 PM PEI MELINDA LITHERLAND Director Apr 21 '26 Option Exercise 0.00 407 0 715 Apr 23 03:25 PM EDWARDS JEFFREY L Director Apr 21 '26 Option Exercise 0.00 407 0 715 Apr 23 03:24 PM PINKSTON ARNOLD A Director Apr 21 '26 Option Exercise 0.00 407 0 715 Apr 23 03:23 PM MICHAEL W CROWLEY Officer Dec 02 '25 Proposed Sale 319.56 776 247,979 Dec 02 06:27 PM Alles Institute for Medical Re Director Nov 18 '25 Proposed Sale 301.04 760 228,793 Nov 18 01:03 PM BARRY JAMES EVP, President, LSG Nov 06 '25 Sale 306.18 700 214,289 510 Nov 10 04:15 PM JAMES BARRY Officer Nov 06 '25 Proposed Sale 306.18 701 214,633 Nov 06 04:24 PM
Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life Science and Clinical Diagnostics. The Life Science segment includes development, manufacturing, and marketing of instruments, systems, reagents, and consumables used to separate, purify, characterize, and quantify biological materials. The Clinical Diagnostics segment focuses on designing, manufacturing, marketing, and support of diagnostic test systems, informatics solutions, test kits, and specialized quality controls for clinical laboratories in the global diagnostics market. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.
Chairman & CEO Mr. Norman D. Schwartz
President & COO Mr. Jonathan P. DiVincenzo
Executive VP & CFO Mr. Roop K. Lakkaraju CPA
Executive VP & President of Life Science Group Mr. James J. Barry
Executive Vice President of Global Commercial Operations Mr. Rajat Mehta
B